Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib

被引：30

作者：

Sakai M. ^{[1
]}

Ishikawa S. ^{[1
]}

Ito H. ^{[2
]}

Ozawa Y. ^{[2
]}

Yamamoto T. ^{[1
]}

Onizuka M. ^{[1
]}

Sakakibara Y. ^{[1
]}

机构：

[1] Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305-8575

[2] Department of Surgery, Tsukuba University Hospital, Tsukuba

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 3期

关键词：

Carcinomatous meningitis; Gefitinib; Non-small-cell lung cancer;

D O I：

10.1007/s10147-005-0558-x

中图分类号：

学科分类号：

摘要：

The prognosis for carcinomatous meningitis remains poor, and focal neurological dysfunctions usually do not improve despite the available treatment options. We report a case of carcinomatous meningitis from non-small-cell lung cancer treated with gefitinib, which brought about a sustained clinical response. A 40-year-old Japanese man was diagnosed with adenocarcinoma in the right lower lobe of the lung, and with multiple pulmonary and brain metastases. Six courses of carboplatin and paclitaxel chemotherapy and gamma-knife radiosurgery induced a near complete response in all lesions. However, 2 months later, cauda equina syndrome and left oculomotor paralysis from carcinomatous meningitis developed rapidly. Magnetic resonance imaging of the brain and spinal cord revealed the enhancement of leptomeningeal disseminations. The patient was treated with 250 mg/day gefitinib. All his neurological symptomatology disappeared within 2 weeks. The shrinkage of the leptomeningeal disseminations was confirmed by follow-up magnetic resonance imaging. The patient is currently doing well and is able to work. Cancer relapse was not observed at 4 months after the initiation of gefitinib. Although the survival benefit is controversial, gefitinib may have a role in the treatment of carcinomatous meningitis from non-small-cell lung cancer to improve neurological dysfunctions. © The Japan Society of Clinical Oncology 2006.

引用

页码：243 / 245

页数：2

共 10 条

[1]

Grossman S.A., Krabak M.J., Leptomeningeal carcinomatosis, Cancer Treat Rev, 25, pp. 103-119, (1999)

[2]

Wasserstrom W.R., Glass J.P., Posner J.B., Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients, Cancer, 49, pp. 759-772, (1982)

[3]

Fukuoka M., Yano S., Giaccone G., Et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J Clin Oncol, 21, pp. 2237-2246, (2003)

[4]

Kris M.G., Natale R.B., Herbst R.S., Et al., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial, JAMA, 290, pp. 2149-2158, (2003)

[5]

Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., Et al., Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis, J Clin Oncol, 11, pp. 561-569, (1993)

[6]

Ceresoli G.L., Cappuzzo F., Gregorc V., Et al., Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial, Ann Oncol, 15, pp. 1042-1047, (2004)

[7]

Chiu C.H., Tsai C.M., Chen Y.M., Et al., Gefitinib is active in patients with brain metastases from non-small-cell lung cancer and response is related to skin toxicity, Lung Cancer, 47, pp. 129-138, (2005)

[8]

Hotta K., Kiura K., Ueoka H., Et al., Effect of gefitinib ("Iressa", ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer, Lung Cancer, 46, pp. 255-261, (2004)

[9]

Van Vulpen M., Kal H.B., Taphoorn M.J., Et al., Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy?, Oncol Rep, 9, pp. 683-688, (2002)

[10]

Lesser G.J., Chemotherapy of cerebral metastases from solid tumors, Neurosurg Clin N Am, 7, pp. 527-536, (1996)

← 1 →